Pfizer/Warner-Lambert
This article was originally published in The Rose Sheet
Executive Summary
Divestiture of one overlapping consumer brand marketed in the U.S. required to receive Federal Trade Commission approval, Pfizer announces. Although the company declined to specifically name FTC's area of concern, it appears most likely Warner-Lambert's Nix and Pfizer's Rid pediculicides would need to be divested. One of the other few potential overlapping areas is mouthwash - W-L markets Listerine and Pfizer sells Plax. The agreement with FTC also involves the divestiture of one early clinical candidate for which the companies have overlapping research programs, Pfizer said. The closing is targeted for early to mid-June, according to Pfizer
You may also be interested in...
Bayer Rid Pediculicide Marketing Emphasis On Mousse Launch
Bayer Consumer Care's inaugural marketing efforts for the newly acquired Rid brand will focus on Maximum Strength Rid Mousse aerosolized foam lice treatment, which began shipping June 22.
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program